Act-HIB, Sanofi Pasteur (1 dose (0.5 ml) after reconstitution contains 10 μg capsular polysaccharideHaemophilus influenzae type B conjugated to tetanus toxoid (18-30 μg).)
Adacel, Sanofi Pasteur (1 dose (0.5 ml) contains not less than 2 IU diphtheria toxoid, not less than 20 IU of tetanus toxoid and pertussis antigens (2.5 μg of pertussis toxoid, 5 μg of filamentous haemagglutinin, 3 μg of pertactin, 5 μg of fimbria type 2 and 3).)
Agrippal, Novartis Vaccines and Diagnostic (1 dose (0.5 ml) contains surface antigens of the influenza virus corresponding to the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The vaccine complies with the WHO recommendations (for the northern hemisphere) and the EU decision for the current season.)
BCG SSI vaccine, Statens Serum Institut (1 dose (0.1 ml) contains 2-8 x 105 CFU live attenuatedMycobacterium bovis. 1 dose (0.05 ml) contains 1-4 x 105 CFU live attenuatedMycobacterium bovis.)
Begrivac, Novartis Vaccines and Diagnostic (1 dose (0.5 ml) contains purified influenza A and B influenza antigens, purified, cleaved and inactivated (the vaccine complies with the WHO recommendation and the EU decision for the current season).)
Bexsero, Novartis Vaccines and Diagnostic (1 dose (0.5 ml) contains: 50 μg recombinant NHBA fusion protein from the strainsNeisseria meningitidis group B, 50 μg of NadA recombinant protein from strainsNeisseria meningitidis group B, 50 μg of recombinant fHbp fusion protein from the strainsNeisseria meningitidis B groups (produced in cellsE. coli using recombinant DNA technology, adsorbed on aluminum hydroxide), 25 μg intimal follicles (OMV) from strain NZ98 / 254Neisseria meningitidis group B - measured as the total amount of protein containing PorA P1.4 antibody (adsorbed on aluminum hydroxide).)
Boostrix, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains not less than 2 IU of dipotoxic toxoid, not less than 20 IU of tetanus toxoid and antigensBordetella pertussis (8 μg of pertussis toxoid, 8 μg of filamentous haemagglutinin, 2.5 μg of pertactin).)
Boostrix Polio, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains not less than 2 IUs of diphtheria toxoid, not less than 20 IU of tetanus toxoid, antigensBordetella pertussis (8 μg of pertussis toxoid, 8 μg of filamentous haemagglutinin, 2.5 μg of pertactin) and inactivated poliovirus (40 U of poliovirus type 1 - strain Mahoney propagated in Vero cell culture, 8 μg of Polio virus type 2 antigen - strain MEF-1 propagated in Vero cell culture, 32 j. Polio virus type 3 antigen - strain Saukett propagated in Vero cell culture).)
Broncho-Vaxom, OM Pharma (1 capsule contains 3.5 mg or 7 mg, 1 sachet contains 3.5 mg of lyophilized bacterial lysates fromHaemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae ssp. Pneumoniaeandssp. ozaenae, Staphylococcus aureus, Streptococcus pyogenes,Streptococcussanguinis and Moraxella catarrhalis.)
Clodivac, IBSS Biomed (1 dose (0.5 ml) of the vaccine contains not less than 40 IU of tetanus toxoid and not less than 5 IU of diphtheria toxoid.)
DTaP SSI vaccine, Statens Serum Institut (0.5 ml (1 dose) contains diphtheria toxin not less than 30 IU (25 Lf), tetanus toxoid not less than 40 IU (7 Lf) and 40 μg of pertussis anatoxin.)
DTaP-IPV SSI vaccine, Statens Serum Institut (0.5 ml (1 dose) contains not less than 30 IU (25 Lf) diphtheria toxoid, not less than 40 IU (7 Lf) tetanus toxoid, 40 μg pertussis toxoid, inactivated polio virus (Salk), type 1 - 40 D antigen units, inactivated polio virus (Salk), type 2 - 8 D antigen units, inactivated polio virus (Salk), type 3 - 32 D antigen units)
Dultavax, Sanofi Pasteur (1 dose (0.5 ml) contains not less than 2 IU diphtheria toxoid, not less than 20 IU of tetanus toxoid and inactivated poliovirus (40 U of polio virus type 1 - Mahoney strain, 8 U of polio virus type D antigen 2 - MEF-1 strain, 32 j. Polio virus type 3 antigen - strain Saukett).)
Engerix B, GlaxoSmithKline Biologicals (1 dose for children (0.5 ml) contains 10 μg, 1 dose for adults (1 ml) contains 20 μg of recombinant hepatitis B virus surface antigen (HBsAg), adsorbed on aluminum hydroxide.)
Euvax B, LG Life Sciences Poland (A vaccine for children: 1 vial of 0.5 ml (1 dose) contains 10 μg of hepatitis B surface antigen.Vaccine for adults: 1 vial 1 ml (1 dose) contains 20 μg of hepatitis B surface antigen.)
Fluarix, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains a split, inactivated influenza virus containing antigens corresponding to the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). the vaccine is updated annually depending on epidemiological data, as recommended by WHO and EU.)
Havrix, GlaxoSmithKline Biologicals (1 dose (1 ml) for adults HAVRIX Adult contains no less than 1440 U. Hepatitis A ELISA. 1 dose (0.5 ml) for children and adolescents HAVRIX 720 Junior contains not less than 720 U. ELISA viral infections hepatitis A.)
HBVax PRO, Sanofi Pasteur MSD (1 vial of 0.5 ml contains 5 μg, 1 vial of 1 ml contains 10 μg, 1 vial of 1 ml contains 40 μg of hepatitis B surface antigen.)
Hepavax-Gene TF, Berna Biotech Italia (1 dose for children (0.5 ml) contains 10 μg of recombinant surface antigen of the virus hepatitis B (HBsAg); 1 adult dose (1 ml) contains 20 μg of recombinant HBsAg.)
Hexacima, Sanofi Pasteur (1 dose (0.5 ml) contains (adsorbed on aluminum hydroxide, hydrated - 0.6 mg Al3+): not less than 20 IU diphtheria toxoid; not less than 40 IU tetanus toxoid; antigensBordatella pertussis (25 μg pertussis toxoid, 25 μg filamentous hemagglutinin); 10 μg of hepatitis B surface antigen (produced in yeast cellsHansenula polymorpha by recombinant DNA); inactivated poliovirus - 40 units of polio virus type 1 antivirus (Mahoney strain propagated in Vero cell culture), 8 j. Polio type 2 antigen D virus (strain MEF-1 propagated in Vero cell culture), 32 j. polio virus D antigen type 3 (Saukett strain grown in Vero cell culture); 12 μg of polysaccharideHaemophilus influenzae type b (polyribosylribitol phosphate) associated with about 22-36 μg of tetanus protein.)
Hiberix ™, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains 10 μg of purified Hib capsular polysaccharide covalently bound to about 20-40 μg tetanus toxoid (PRP-T).)
IDflu, Sanofi Pasteur (1 dose (0.1 ml) contains the split, inactivated influenza virus of the following strains: A (H1N1) - 9 μg or 15 μg HA, A (H3N2) - 9 μg or 15 μg HA and B - 9 μg or 15 μg HA (HA - haemagglutinin). The vaccine complies with the WHO recommendations (for the northern hemisphere) and the EU decision for the current season.)
Imovax Polio, Sanofi Pasteur (1 dose (0.5 ml) contains: 40 U of the inactivated virus D antigenpolio type 1; 8 j. D antigen of inactivated viruspolio type 2; 32 μg of inactivated virus D antigenpolio type 3.)
Infanrix hexa, GlaxoSmithKline Biologicals (1 dose (0.5 ml) after reconstitution contains: not less than 30 IU of diphtheria toxoid adsorbed to aluminum hydroxide, not less than 40 IU of tetanus toxoid adsorbed to aluminum hydroxide; antigensBordatella pertusis (25 μg of pertussis toxoid adsorbed to aluminum hydroxide, 25 μg of filamentous hemagglutinin adsorbed to aluminum hydroxide, 8 μg of pertactin adsorbed on aluminum hydroxide); 10 μg surface antigen of the recombinant virushepatitis B adsorbed on aluminum phosphate; inactivated poliovirus - 40 units of polio virus type 1 antivirus (Mahoney strain propagated in Vero cell culture), 8 j. Polio type 2 antigen D virus (strain MEF-1 propagated in Vero cell culture), 32 j. polio virus D antigen type 3 (Saukett strain grown in Vero cell culture); 10 μg of polysaccharideHaemophilus influenzae type b (polysibosylribitol phosphate) adsorbed on aluminum phosphate, bound to about 25 μg of tetanus toxoid as a protein carrier.)
Infanrix ™ - DTPa, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains not less than 30 IU of diphtheria toxoids adsorbed to aluminum hydroxide, not less than 40 IU of tetanus toxoid adsorbed to aluminum hydroxide and antigensBordetella pertussis (25 μg pertussis toxoid, 25 μg filamentous hemagglutinin, 8 μg pertactin) adsorbed on aluminum hydroxide.)
Infanrix ™ - IPV + Hib, GlaxoSmithKline Biologicals (1 dose (0.5 ml) after reconstitution contains: not less than 30 IU of diphtheria toxoid adsorbed to aluminum hydroxide, not less than 40 IU of tetanus toxoid adsorbed to aluminum hydroxide; antigensBordatella pertusis (25 μg of pertussis toxoid adsorbed to aluminum hydroxide, 25 μg of filamentous hemagglutinin adsorbed to aluminum hydroxide, 8 μg of pertactin adsorbed on aluminum hydroxide); inactivated poliovirus - 40 units of polio virus type 1 antivirus (Mahoney strain propagated in Vero cell culture), 8 j. Polio type 2 antigen D virus (strain MEF-1 propagated in Vero cell culture), 32 j. polio virus D antigen type 3 (Saukett strain grown in Vero cell culture); 10 μg of polysaccharideHaemophilus influenzae type b (polyribosylribitol phosphate), associated with about 20-40 μg of tetanus toxoid as a protein carrier.)
Inflexal V, Crucell Italy (1 dose of 0.5 ml contains inactivated viral surface antigens corresponding to the following strains: A (H3N2) - 15 μg, A (H1N1) - 15 μg and B - 15 μg.)
Influvac, BGP Products B.V. (1 dose (0.5 ml) contains surface antigens of the influenza virus corresponding to the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The vaccine complies with the WHO recommendations (for the northern hemisphere) and the EU decision for the current season.)
M-M-R® II, MSD Polska (1 vial (1 dose) contains: measles virus (strain Enders-Edmonston) - not less than 1000 CCID50, mumps virus (Jeryl Lynn strain) - not less than 5000 CCID50, rubella virus (strain Wistar RA 27/3) - not less than 1000 CCID50.)
M-M-RVAXPRO, Sanofi Pasteur MSD (1 dose (0.5 ml) contains live, attenuated viruses: measles (strain Enders - Edmonston) - not less than 1 × 103 CCID50, mumps (Jeryl Lynn strain) - not less than 12,5 × 103 CCID50, rubella (strain Wistar RA 27/3) - not less than 1 × 103 CCID50 . CCID50 - infectious dose for 50% of the culture cells.)
Meningo A + C, Sanofi Pasteur (1 dose (0.5 ml) of the reconstituted vaccine contains polysaccharidesNeisseria meningitidis from group A - 50 μg and from group C - 50 μg.)
Menitorix, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains 5 μg of polysaccharideHaemophilus type b associated with tetanus toxoid as a protein carrier (12.5 μg) and 5 μg of polysaccharideNeisseria meningitidis group C (strain C11) bound to tetanus toxoid as a protein carrier (5 μg). The drug contains sodium (75 μmol / dose).
Menveo, Novartis Vaccines and Diagnostic (1 dose of vaccine (0.5 ml) contains: 10 μg of group A meningococcal oligosaccharide, 5 μg of group C meningococcal oligosaccharide, 5 μg of W135 meningococcal group oligosaccharide and 5 μg of group Y meningococcal oligosaccharide, conjugated to CRM protein197Corynebacterium diphtheriae. )
NeisVac-C, Baxter Polska (1 dose (0.5 ml) contains 10 μg of polysaccharideNeisseria meningitidis C (strain C 11) conjugated with 10-20 μg of tetanus toxoid and adsorbed to aluminum hydroxide.)
Nimenrix, GlaxoSmithKline Biologicals (1 dose of vaccine (0.5 ml) contains 5 μg of polysaccharideNeisseria meningitidis A group, 5 μg of polysaccharideNeisseria meningitidis C group, 5 μg polysaccharideNeisseria meningitidis W-135 groups and 5 μg polysaccharideNeisseria meningitidis group Y.)
PedvaxHIB, MSD Polska (1 vial (0.5 ml) contains 7.5 μg of polyribiborbitol phosphate (PRP)Haemophilus influenzae type b, adsorbed on aluminum hydroxide, coupled with 125 μg of the outer membrane complex of the outer B grouping of meningococci B)
Pentaxim ™, Sanofi Pasteur (1 dose (0.5 ml) contains not less than 30 IU of dipotoxic toxoid, not less than 40 IU of tetanus toxoid, 25 μg of pertussis toxoid, 25 μg of pertussis haemagglutinin, 40 U of inactivated virus D antigenpolio type 1, 8 j. of antigen D inactivated viruspolio type 2, 32 U of inactivated virus D antigenpolio type 3, 10 μg of polysaccharideHaemophilus influenzae type B conjugated with 18-30 μg tetanus toxoid as a protein carrier.)
Priorix-Tetra, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains: not less than 103 CCID50 measles virus of the Schwarz strain, not less than 104,4 CCID50 mumps virus strain RIT 4385 (derived from the strain Jeryl Lynn), not less than 103 CCID50 rubella virus Wistar RA 27/3 and not less than 103,3 PFU of chickenpox virus strain OKA.)
Priorix ™, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains live attenuated measles viruses (Schwarz strain), mumps viruses (strain RIT 4385) and rubella viruses (strain Wistar RA 27/3).)
Pseudovac, IBSS Biomed (1 ml of the vaccine contains antigensPseudomonas aeruginosa - 7 immunotypes.)
Rotarix, GlaxoSmithKline Biologicals (1 dose (1.5 ml) contains not less than 106 CCID50 human rotavirus, live, attenuated. The product contains sucrose.)
RotaTeq, Sanofi Pasteur MSD (1 dose (2 ml) contains not less than 2.2 x 106 IU rotavirus serum G1, 2.8 x 106 IU rotavirus serotype G2, 2.2 x 106 IU rotavirus G3 serum, 2.0 x 106 IU rotavirus serotype G4 and 2.3 x 106 IU of the P1 serotype rotavirus [8]. The product contains sucrose.)
Rouvax, Sanofi Pasteur (1 vial contains no less than 1000 TCIDs50 live attenuated measles virus (Schwarz strain) in the form of lyophilisate.)
Stamaril, Sanofi Pasteur (1 dose (0.5 ml) contains: not less than 1000 LD units50 live attenuated yellow fever virus (strain 17 D-204).)
Synflorix, GlaxoSmithKline Biologicals (1 dose (0.5 ml) contains a mixture of pneumococcal polysaccharides serotypes: 1 - 1 μg, 4 - 3 μg, 5 - 1 μg, 6B - 1 μg, 7F - 1 μg, 9V - 1 μg, 14 - 1 μg, 18C - 3 μg, 19F - 3 μg, 23F - 1 μg adsorbed on aluminum phosphate (0.5 mg) Polysaccharides, serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F, are conjugated to carrier protein D derived from non-enveloped strainsHaemophilus influenzae (9-16 μg). The polysaccharide serotype 18C is conjugated to tetanus toxoid as a protein carrier (5-10 μg). Polysaccharide 19F serotype is conjugated with diphtheria toxoid as a protein carrier (3-6 μg).)
BCG tuberculosis vaccine, Biomed Lublin (1 dose (0.1 ml) contains 50 μg of half-dry BCG mycobacteria which corresponds to 150,000 to 600,000 BCG live bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau transplant. 10-dose vaccine.)
Adsorptive tetanus vaccine (T), Biomed Warsaw (1 dose (0.5 ml) contains not less than 40 IU of tetanus toxoid adsorbed on aluminum hydroxide, hydrated (not more than 1.25 mg of Al3+).)
Tetana, IBSS Biomed (1 dose (0.5 ml) contains not less than 40 IU of tetanus toxoid.)
Tripacel, Sanofi Pasteur (1 dose (0.5 ml) of the vaccine contains: not less than 30 IU of dipotoxic toxoid, not less than 40 IU of tetanus toxoid, 10 μg of pertussis toxoid (PT), 5 μg of tissue haemagglutinin (FHA), 3 μg of pertactin (PRN) and 5 μg of type 2 and 3 fimbriae (FIM).)
Twinrix™, GlaxoSmithKline Biologicals (1 dose (1 ml) of the vaccine contains: 720 units of inactivated hepatitis A virus adsorbed to aluminum hydroxide and 20 μg of recombinant HBsAg surface antigen adsorbed on aluminum phosphate.)
Ty-Major vaccine, IBSS Biomed (1 dose (0.5 ml) contains not less than 5x108 and not more than 1x109 inactivated typhoid bacilli.)
TyT-Sero-tetanus vaccine, IBSS Biomed (1 dose (0.5 ml) contains: not less than 5x108 and not more than 1x109 inactivated bacteriaSalmonella typhi and not less than 20 IU tetanus toxoid.)
Vaqta, MSD Polska (1 dose of vaccine (0.5 ml or 1 ml) contains 25 U or 50 U of inactivated hepatitis A.)
Vaxigrip, Sanofi Pasteur (1 dose (0.5 ml) contains the split, inactivated influenza virus of the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The vaccine complies with WHO recommendations (for the Northern Hemisphere) and EU decision for the current season.)
Verorab, Sanofi Pasteur (1 dose (0.5 ml) contains at least 2.5 IU of inactivated rabies virus (strain Wistar Rabies PM / WI38 1503-3M) propagated in VERO cells.)
(C)
